Sussex Research Laboratories Inc., a globally recognized and leading specialist empowering therapeutic innovation through glycoscience, is pleased to announce that it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support advancements in oligonucleotide therapeutics via glycoscience. The project, conducted in partnership with a UK-based industrial partner and Canadian professor, Dr. Matthew Macauley of the University of Alberta, is poised to drive cutting-edge advancements in the field of oligonucleotide and mRNA therapeutics. This project is part of the Canada-UK biomanufacturing initiative that was mentioned in the Joint Statement by Prime Minister Carney and Prime Minister Starmer Press Release.

Sussex Research will develop innovative, flexible and scalable glycan-based technologies that will significantly contribute to precision delivery. The U.K. partner will apply and test the targeting ligands’ effectiveness in their oligonucleotide therapeutic system. The collaboration will enable efficiency and cost-effectiveness of manufacturing next-generation biological therapeutics and delivery systems. This international collaboration represents a major milestone in fostering transatlantic scientific innovation in an area of therapeutic development that is expected to undergo explosive growth in coming years.